FGF2 and scleroderma: They identified NTN1, VEGFD, MMP2, FGF2, and FNDC5 as potential players in how the ADSCs secretome may disrupt vascular and perivascular inflammation hubs in scleroderma and thereby promote angiogenesis and lymphangiogenesis.